Prof. Dr. İrfan Çiçin

Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

DOI 10.21673/anadoluklin.1675424 Texte intégral en libre accèsSource : OpenAlex

Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

JCO Global Oncology, 2026

DOI 10.1200/go-25-00234 PMID 41855443 Texte intégral en libre accèsSource : OpenAlex

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study

Journal of Clinical Oncology, 2026

DOI 10.1200/jco-25-00826 PMID 41538748 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer

JAMA Oncology, 2026

DOI 10.1001/jamaoncol.2026.1645 PMID 42240984 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

JTO Clinical and Research Reports, 2026

DOI 10.1016/j.jtocrr.2026.100988 PMID 42368479 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey

Scientific Reports, 2026

DOI 10.1038/s41598-026-61177-3 PMID 42414499 Texte intégral en libre accèsSource : OpenAlex

Telemedicine adoption, pandemic-related fear, and treatment adherence in cancer care during COVID-19: a prospective cohort study

Supportive Care in Cancer, 2026

DOI 10.1007/s00520-026-10748-1 PMID 42081154 Texte intégral en libre accèsSource : OpenAlex

Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1

JTO Clinical and Research Reports, 2026

DOI 10.1016/j.jtocrr.2026.101029 PMID 42529322 Texte intégral en libre accèsSource : OpenAlex

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study

The Breast, 2026

DOI 10.1016/j.breast.2026.104838 PMID 42309024 Texte intégral en libre accèsSource : OpenAlex

Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions

European Journal of Cancer Care, 2026

DOI 10.48130/ejcc-0026-0010 Source : OpenAlex

Clinical Characteristics, Treatment Patterns, and Survival Outcomes of Right-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer: A Real-World Multicenter Cohort Study

Clinics and Practice, 2026

DOI 10.3390/clinpract16090158 PMID 42783081 Texte intégral en libre accèsSource : OpenAlex

Triggering receptors expressed on myeloid cells (TREM-1) and TREM-2 as predictors of pathological complete response to neoadjuvant therapy in triple-negative breast cancer

Breast Cancer, 2026

DOI 10.1007/s12282-026-01918-4 PMID 42766275 Texte intégral en libre accèsSource : OpenAlex

Consent architecture in biobanking: ethical attitudes and consent preferences among people with cancer and caregivers

BMC Cancer, 2026

DOI 10.1186/s12885-026-17118-4 Texte intégral en libre accèsSource : OpenAlex

KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri

DergiPark (Istanbul University), 2025

Source : OpenAlex

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Journal of Thoracic Oncology, 2025

DOI 10.1016/j.jtho.2025.07.117 PMID 40923969 45 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Journal of Thoracic Oncology, 2025

DOI 10.1016/j.jtho.2025.03.033 PMID 40118215 36 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

Medicina, 2025

DOI 10.3390/medicina61010123 PMID 39859105 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Understanding of Clinical Trials Among Patients With Cancer and Their Relatives

JAMA Network Open, 2025

DOI 10.1001/jamanetworkopen.2024.57020 PMID 39874033 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%

Cancer, 2025

DOI 10.1002/cncr.35864 PMID 40323717 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

The Lancet Respiratory Medicine, 2025

DOI 10.1016/s2213-2600(25)00209-7 PMID 40983066 1 citation (Europe PMC) Source : OpenAlex

Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy

The Breast, 2025

DOI 10.1016/j.breast.2025.104669 PMID 41387082 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

Future Oncology, 2025

DOI 10.1080/14796694.2025.2489339 PMID 40371894 Texte intégral en libre accèsSource : OpenAlex

Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study

Future Oncology, 2025

DOI 10.1080/14796694.2025.2527477 PMID 40704651 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

EPH236 The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye

Value in Health, 2025

DOI 10.1016/j.jval.2025.09.1365 Source : OpenAlex

EPH237 The Health Impact of Pembrolizumab for the First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC) That Expresses High Levels of PD-L1 in Türkiye

Value in Health, 2025

DOI 10.1016/j.jval.2025.09.1366 Source : OpenAlex

EPH240 The Health Impact of Pembrolizumab Plus Chemotherapy in the First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC) in Türkiye

Value in Health, 2025

DOI 10.1016/j.jval.2025.09.1369 Source : OpenAlex

EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

Value in Health, 2025

DOI 10.1016/j.jval.2025.09.1368 Source : OpenAlex

EPH238 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Nonsquamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

Value in Health, 2025

DOI 10.1016/j.jval.2025.09.1367 Source : OpenAlex

Impact of Dose Reductions on Efficacy of Adjuvant Abemaciclib for Patients with High Risk Early Breast Cancer (EBC): Analyses from the monarchE Study

Trakya University's Institutional Open Access System (Trakya University), 2025

Texte intégral en libre accèsSource : OpenAlex

Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

Clinical Genitourinary Cancer, 2024

DOI 10.1016/j.clgc.2024.102077 PMID 38626660 2 citations (Europe PMC) Source : OpenAlex

A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Medicine, 2024

DOI 10.1097/md.0000000000037972 PMID 38787994 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Journal of Oncology Pharmacy Practice, 2024

DOI 10.1177/10781552241241004 PMID 38613329 Texte intégral en libre accèsSource : OpenAlex

The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 citations (Europe PMC) Source : OpenAlex

The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study—Real-world data.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.e20006 Texte intégral en libre accèsSource : OpenAlex

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.23.01994 PMID 38194616 195 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.24.00720 PMID 38843488 172 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.24.00733 PMID 38843511 132 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.23.02110 PMID 38648575 30 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

npj Breast Cancer, 2024

DOI 10.1038/s41523-024-00639-1 PMID 38671001 30 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

EBioMedicine, 2024

DOI 10.1016/j.ebiom.2024.105374 PMID 39395231 19 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

BMC Cancer, 2024

DOI 10.1186/s12885-023-11213-6 PMID 39054485 20 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Clinical Genitourinary Cancer, 2024

DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 citations (Europe PMC) Source : OpenAlex

Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer

JCO Global Oncology, 2024

DOI 10.1200/go.24.00201 PMID 39208383 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2403051 PMID 39257075 2 citations (Europe PMC) Source : OpenAlex

Potential predictor of prognosis in breast carcinoma: Tumor budding

Indian Journal of Pathology and Microbiology, 2024

DOI 10.4103/ijpm.ijpm_300_24 PMID 40682770 Texte intégral en libre accèsSource : OpenAlex

A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials

Immunotherapy, 2024

DOI 10.2217/imt-2023-0184 PMID 38197142 1 citation (Europe PMC) Source : OpenAlex

Pilomatrix Carcinoma with Pulmonary Metastasis

Journal of Oncological Sciences, 2024

DOI 10.37047/jos.2023-99357 4 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.103 11 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.17_suppl.lba8500 8 citations (OpenAlex) Source : OpenAlex

Abstract PO3-04-12: SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Cancer Research, 2024

DOI 10.1158/1538-7445.sabcs23-po3-04-12 3 citations (OpenAlex) Source : OpenAlex